Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TG Therapeutics, Inc. - Common Stock
(NQ:
TGTX
)
54.70
-0.17 (-0.31%)
Streaming Delayed Price
Updated: 2:51 PM EDT, Jul 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about TG Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
TG Therapeutics (NASDAQ:TGTX) Meets Minervini's Trend Template with Accelerating Growth
↗
Today 8:30 EDT
Via
Chartmill
2 Fast-Growing Pharmaceutical Stocks to Buy Now
↗
July 08, 2026
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.
Via
The Motley Fool
TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength
↗
July 02, 2026
Via
Chartmill
TG Therapeutics Stock Surges After Drug Trial Update
↗
June 03, 2026
Shares of TG Therapeutics Inc (NASDAQ: TGTX) are climbing Wednesday after early-stage clinical trial data for new BRIUMVI MS formulation.
Via
Benzinga
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
↗
May 30, 2026
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
Via
The Motley Fool
Topics
Regulatory Compliance
TG THERAPEUTICS INC (NASDAQ:TGTX) Screens as Affordable Growth Play with Strong Revenue Surge and Discounted Valuation
↗
May 09, 2026
Via
Chartmill
TG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Beat Revenue Guidance but Miss EPS Estimates
↗
May 06, 2026
Via
Chartmill
Topics
Earnings
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position
↗
May 10, 2026
This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.
Via
The Motley Fool
Topics
Regulatory Compliance
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
↗
May 10, 2026
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Via
The Motley Fool
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript
↗
May 06, 2026
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript
Via
The Motley Fool
TG Therapeutics Inc (NASDAQ:TGTX) Shows Strong Growth and Technical Setup for Potential Upside
↗
April 20, 2026
Via
Chartmill
TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum
↗
April 04, 2026
Via
Chartmill
TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup
↗
March 14, 2026
Via
Chartmill
TGTX Q1 2025 Earnings Call Transcript
↗
May 06, 2026
TGTX Q1 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment
↗
March 16, 2026
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop
↗
March 16, 2026
This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
Via
The Motley Fool
TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook
↗
February 26, 2026
Via
Chartmill
Topics
Earnings
TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally
↗
January 15, 2026
Via
Stocktwits
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript
↗
February 26, 2026
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript
Via
The Motley Fool
Soleus Adds a Significant Number of Celcuity Shares
↗
February 13, 2026
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.
Via
The Motley Fool
TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win'
↗
February 09, 2026
TG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression.
Via
Stocktwits
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares
↗
February 02, 2026
This commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse clinical pipeline.
Via
The Motley Fool
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?
↗
January 14, 2026
On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.
Via
Stocktwits
Topics
Artificial Intelligence
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026
↗
January 13, 2026
The company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S.
Via
Stocktwits
Topics
Artificial Intelligence
These stocks are moving in today's after hours session
↗
January 13, 2026
Via
Chartmill
TG Therapeutics TGTX Q3 2025 Earnings Transcript
↗
November 27, 2025
TG Therapeutics TGTX Q3 2025 Earnings Transcript
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 11, 2025
Via
Benzinga
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results
↗
November 10, 2025
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics.
Via
Investor's Business Daily
Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million
↗
November 03, 2025
Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
↗
November 03, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
